Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||RET - SEPTIN9|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RET - SEPTIN9||malignant pheochromocytoma||predicted - sensitive||Selpercatinib||Case Reports/Case Series||Actionable||In a clinical case study, Retevmo (selpercatinib) treatment resulted in a partial response with 46% reduction in lesions, which was ongoing at 23 weeks, in a patient with malignant pheochromocytoma harboring a RET-SEPTIN9 fusion (PMID: 34994633).||34994633|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|